Kukoamine B

Drug Profile

Kukoamine B

Alternative Names: C 17616; KB; kukoamine B mesilate

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator Tianjin Chase Sun Pharmaceutical
  • Class Alkaloids; Antiseptics; Biogenic amines; Caffeic acids; Polyamines; Small molecules
  • Mechanism of Action Bacterial DNA inhibitors; Lipopolysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sepsis

Most Recent Events

  • 26 Feb 2016 Tianjin Chasesun Pharmaceutical plans a phase I trial in Healthy volunteers in China (NCT02690961)
  • 01 Apr 2015 Tianjin Chasesun Pharmaceutical completes a phase I trial in Healthy volunteers in China (NCT02219971)
  • 01 Aug 2014 Phase I clinical trials in Sepsis (In volunteers) in China (IV) (NCT02219971)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top